Results
1 -
2 of
2First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies, Investigational New Drugs In vitro and in vivo activity of melflufen (J1) in lymphoma, BMC Cancer